TY - JOUR
T1 - Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacity.
AU - Thomsen, J J
AU - Rentsch, R L
AU - Robach, P
AU - Calbet, J A L
AU - Boushel, R
AU - Rasmussen, P
AU - Juel, C
AU - Lundby, C
N1 - Keywords: Absorptiometry, Photon; Adiposity; Adult; Anaerobic Threshold; Athletic Performance; Bicycling; Body Composition; Body Mass Index; Body Weight; Erythropoietin, Recombinant; Exercise Test; Hematocrit; Hemoglobins; Humans; Lactic Acid; Male; Oxygen Consumption; Single-Blind Method
PY - 2007
Y1 - 2007
N2 - The effects of recombinant human erythropoietin (rHuEpo) treatment on aerobic power (VO2max) are well documented, but little is known about the effects of rHuEpo on submaximal exercise performance. The present study investigated the effect on performance (ergometer cycling, 20-30 min at 80% of maximal attainable workload), and for this purpose eight subjects received either 5,000 IU rHuEpo or placebo every second day for 14 days, and subsequently a single dose of 5,000 IU/placebo weekly/10 weeks. Exercise performance was evaluated before treatment and after 4 and 11 weeks of treatment. With rHuEpo treatment VO2max increased (P<0.05) by 12.6 and 11.6% in week 4 and 11, respectively, and time-to-exhaustion (80% VO2max) was increased by 54.0 and 54.3% (P<0.05) after 4 and 11 weeks of treatment, respectively. However, when normalizing the workload to the same relative intensity (only done at time point week 11), TTE was decreased by 26.8% as compared to pre rHuEpo administration. In conclusion, in healthy non-athlete subjects rHuEpo administration prolongs submaximal exercise performance by about 54% independently of the approximately 12% increase in VO2max.
AB - The effects of recombinant human erythropoietin (rHuEpo) treatment on aerobic power (VO2max) are well documented, but little is known about the effects of rHuEpo on submaximal exercise performance. The present study investigated the effect on performance (ergometer cycling, 20-30 min at 80% of maximal attainable workload), and for this purpose eight subjects received either 5,000 IU rHuEpo or placebo every second day for 14 days, and subsequently a single dose of 5,000 IU/placebo weekly/10 weeks. Exercise performance was evaluated before treatment and after 4 and 11 weeks of treatment. With rHuEpo treatment VO2max increased (P<0.05) by 12.6 and 11.6% in week 4 and 11, respectively, and time-to-exhaustion (80% VO2max) was increased by 54.0 and 54.3% (P<0.05) after 4 and 11 weeks of treatment, respectively. However, when normalizing the workload to the same relative intensity (only done at time point week 11), TTE was decreased by 26.8% as compared to pre rHuEpo administration. In conclusion, in healthy non-athlete subjects rHuEpo administration prolongs submaximal exercise performance by about 54% independently of the approximately 12% increase in VO2max.
U2 - 10.1007/s00421-007-0522-8
DO - 10.1007/s00421-007-0522-8
M3 - Journal article
C2 - 17668232
SN - 1439-6319
VL - 101
SP - 481
EP - 486
JO - European Journal of Applied Physiology
JF - European Journal of Applied Physiology
IS - 4
ER -
